136 related articles for article (PubMed ID: 8380592)
21. Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line.
Webb CD; Latham MD; Lock RB; Sullivan DM
Cancer Res; 1991 Dec; 51(24):6543-9. PubMed ID: 1660341
[TBL] [Abstract][Full Text] [Related]
22. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC
Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057
[TBL] [Abstract][Full Text] [Related]
23. Novel selection and genetic characterisation of an etoposide-resistant human leukaemic CCRF-CEM cell line.
Patel S; Fisher LM
Br J Cancer; 1993 Mar; 67(3):456-63. PubMed ID: 8382508
[TBL] [Abstract][Full Text] [Related]
24. Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage.
Robinson MJ; Martin BA; Gootz TD; McGuirk PR; Moynihan M; Sutcliffe JA; Osheroff N
J Biol Chem; 1991 Aug; 266(22):14585-92. PubMed ID: 1650363
[TBL] [Abstract][Full Text] [Related]
25. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells.
Sullivan DM; Latham MD; Ross WE
Cancer Res; 1987 Aug; 47(15):3973-9. PubMed ID: 3038304
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM
Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144
[TBL] [Abstract][Full Text] [Related]
27. Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine.
Nitiss JL; Vilalta PM; Wu H; McMahon J
Mol Pharmacol; 1994 Oct; 46(4):773-7. PubMed ID: 7969059
[TBL] [Abstract][Full Text] [Related]
28. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
Kawanami K; Nakamura T; Ono M; Kusano T; Okada K; Kikuchi A; Adachi N; Kohno K; Higashi K; Kuwano M
Oncol Res; 1996; 8(5):197-206. PubMed ID: 8884812
[TBL] [Abstract][Full Text] [Related]
29. Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line.
Sullivan DM; Eskildsen LA; Groom KR; Webb CD; Latham MD; Martin AW; Wellhausen SR; Kroeger PE; Rowe TC
Mol Pharmacol; 1993 Feb; 43(2):207-16. PubMed ID: 8094226
[TBL] [Abstract][Full Text] [Related]
30. Cloning and characterization of full-length cDNAs coding for the DNA topoisomerase II beta from Chinese hamster lung cells sensitive and resistant 9-OH-ellipticine.
Dereuddre S; Frey S; Delaporte C; Jacquemin-Sablon A
Biochim Biophys Acta; 1995 Nov; 1264(2):178-82. PubMed ID: 7495861
[TBL] [Abstract][Full Text] [Related]
31. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
[TBL] [Abstract][Full Text] [Related]
32. Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA.
Gudkov AV; Zelnick CR; Kazarov AR; Thimmapaya R; Suttle DP; Beck WT; Roninson IB
Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3231-5. PubMed ID: 8386368
[TBL] [Abstract][Full Text] [Related]
33. Increased phosphorylation of DNA topoisomerase II in etoposide resistant mutants of human glioma cell line.
Matsumoto Y; Kunishio K; Nagao S
J Neurooncol; 1999; 45(1):37-46. PubMed ID: 10728908
[TBL] [Abstract][Full Text] [Related]
34. In vivo etoposide-resistant C6 glioma cell line: significance of altered DNA topoisomerase II activity in multi-drug resistance.
Taki T; Ohnishi T; Arita N; Hiraga S; Hayakawa T
J Neurooncol; 1998 Jan; 36(1):41-53. PubMed ID: 9525824
[TBL] [Abstract][Full Text] [Related]
35. Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide.
Liu YX; Hsiung Y; Jannatipour M; Yeh Y; Nitiss JL
Cancer Res; 1994 Jun; 54(11):2943-51. PubMed ID: 8187080
[TBL] [Abstract][Full Text] [Related]
36. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells.
Kubo T; Kohno K; Ohga T; Taniguchi K; Kawanami K; Wada M; Kuwano M
Cancer Res; 1995 Sep; 55(17):3860-4. PubMed ID: 7641205
[TBL] [Abstract][Full Text] [Related]
37. DNA topoisomerase: the mechanism of resistance to DNA topoisomerase II inhibitor VP-16.
Hong JH
Hiroshima J Med Sci; 1989 Dec; 38(4):197-207. PubMed ID: 2561562
[TBL] [Abstract][Full Text] [Related]
38. The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine.
Jannatipour M; Liu YX; Nitiss JL
J Biol Chem; 1993 Sep; 268(25):18586-92. PubMed ID: 8395511
[TBL] [Abstract][Full Text] [Related]
39. Modulation of drug sensitivity in yeast cells by the ATP-binding domain of human DNA topoisomerase IIalpha.
Vilain N; Tsai-Pflugfelder M; Benoit A; Gasser SM; Leroy D
Nucleic Acids Res; 2003 Oct; 31(19):5714-22. PubMed ID: 14500835
[TBL] [Abstract][Full Text] [Related]
40. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.
Ritke MK; Roberts D; Allan WP; Raymond J; Bergoltz VV; Yalowich JC
Br J Cancer; 1994 Apr; 69(4):687-97. PubMed ID: 8142256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]